NCT03444701: A Study of E7130 in Participants With Solid Tumors

NCT03444701
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated or active brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03444701

Comments are closed.

Up ↑